ConvaTec Group PLC -6.3% potential downside indicated by RBC Capital Markets

ConvaTec Group PLC with ticker (LON:CTEC) now has a potential downside of -6.3% according to RBC Capital Markets.



RBC Capital Markets set a target price of 195 GBX for the company, which when compared to the ConvaTec Group PLC share price of 207 GBX at opening today (25/11/2021) indicates a potential downside of -6.3%. Trading has ranged between 185 (52 week low) and 265 (52 week high) with an average of 3,873,853 shares exchanging hands daily. The market capitalisation at the time of writing is £4,076,141,840.

ConvaTec Group PLC is a United Kingdom-based medical product and technology company. The Company focuses on therapies for the management of chronic conditions, including products used for advanced chronic and acute wound care, ostomy care, continence and critical care and infusion devices used in the treatment of diabetes and other conditions. It operates across market franchises, such as Advanced Wound Care, which provides advanced wound dressings and skin care products; Ostomy Care, which provides devices, accessories and services for people with a stoma, resulting from colorectal cancer, inflammatory bowel disease, bladder cancer, obesity and other causes; Continence and Critical Care, which provides products for people with urinary continence issues related to spinal cord injuries, multiple sclerosis, spina bifida and other causes, and Infusion Devices, which provide disposable infusion sets.